Looking Ahead: Predictions for Cardiology in 2026

"As datasets expand to include sociodemographic, environmental, clinical, imaging, and molecular features, new data science methods will model these complex interconnections—deepening our understanding of cardiovascular disease and guiding strategies to maximize wellbeing and healthspan."

Pradeep Natarajan, MD, PhD
Physician Investigator
Heart and Vascular Institute

"In 2026, self-critical, real-world evidence will matter more than ever. It will complement randomized controlled trials, providing insights that directly inform decision-making, and improve patient outcomes."

Nils Krüger, PhD
Investigator
Heart and Vascular Institute

"By 2026, I predict that we will be able to characterize women’s cardiovascular risk with more biological precision, particularly around how adverse pregnancy outcomes and the menopause transition alter vascular biology and cardiometabolic pathways. I hope to see early trials and cohort studies that explicitly incorporate reproductive history, menopause status, and a focused panel of biomarkers into risk stratification, moving beyond traditional 'one-size-fits-all' algorithms. Together, these advances can lay the groundwork for more tailored prevention strategies in women’s heart health."

Emily Lau, MD
Physician Investigator
Heart and Vascular Institute

“By 2026, AI will redefine cardiovascular trials—automating event adjudication across imaging, EHRs, and wearables, cutting costs, and shifting endpoints from late clinical events to early imaging-derived biomarkers. This evolution will enable smaller, faster studies that capture treatment effects sooner and with greater precision.”

Shady Abohashem, MD
Physician Investigator
Heart and Vascular Institute